Dr. Inderbir Gill, director of the USC Institute of Urology, was the cover story feature on the August 2015 issue of the Urology Times (vol 43). The topic is “Surgical advances, minimally invasive oncologic surgery – the best is yet to come.”. This article is available at urologytimes.modernmedicine.com:
The use of minimally invasive surgery in urology has evolved and expanded since its inception. Inderbir S. Gill, MD, MCh, who is widely considered the international leader in minimally invasive urologic oncologic surgery, says the best is yet to come. In this interview, Dr. Gill discusses what he calls the three most significant advances in minimally invasive oncologic surgery, how the current model for education can be improved, and the next frontier in minimally invasive surgery. Dr. Gill is chairman and professor of the Catherine and Joseph Aresty Department of Urology at the University of Southern California (USC), founding executive director of the USC Institute of Urology, and associate dean of clinical innovation at the Keck School of Medicine of USC. He served as a consultant for Mimic Technologies, which has developed a surgical simulator in conjunction with USC.Dr. Gill was interviewed by Urology Times Editorial Consultant Stephen Y. Nakada, MD, The Uehling Professor and founding chairman of the department of urology at the University of Wisconsin, Madison.
What would you say are the three greatest advances in minimally invasive surgery in the last quarter century?
The biggest advance has been the substantially increased application of minimally invasive urologic/oncologic surgery. In 2015, we are now able to bring a confident, even an increasingly dominant presence in this arena. This has taken a quarter of a century to come to fruition.
Second are the advances in robotic technology that have further improved our ability to do minimally invasive surgery. I personally used to be a laparoscopic aficionado. Now, for a host of very good reasons, I have become a convert to robotic surgery.
Third is the increasing push toward obtaining level one evidence—randomized, controlled trials. Gone are the days of do one, see one, teach one. Now, appropriately, far more robust and dependable level one data are required.
Source: Urology Times